Your activity: 16 p.v.

Antibiotics for treatment of bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA) in adults[1-4]

Antibiotics for treatment of bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA) in adults[1-4]
Drug Adult dose
Antibiotics of choice
Vancomycin

Loading dose*: 20 to 35 mg/kg

Initial maintenance dose and interval determined by nomogram; typically 15 to 20 mg/kg every 8 to 12 hours for most patients with normal renal function

Subsequent dose and interval adjustments based on AUC-guided (preferred) or trough-guided serum concentration monitoringΔ
Daptomycin 8 to 10 mg/kg IV once daily
Teicoplanin 6 to 12 mg/kg IV once daily
Alternative agents
Ceftaroline 600 mg IV every 8 hours
Telavancin 10 mg/kg IV once daily
Linezolid 600 mg IV (or orally) twice daily

AUC: area under the 24-hour time-concentration curve; IV: intravenously.

* The vancomycin loading dose is based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg. Within this range, we use a higher dose for critically ill patients.

¶ Refer to the UpToDate topic on vancomycin dosing for sample nomogram.

Δ Refer to the UpToDate topic on vancomycin dosing for discussion of AUC-guided and trough-guided vancomycin dosing.

◊ Daptomycin dosing for treatment of bacteremia (as approved by the US Food and Drug Administration) is 6 mg/kg IV once daily; however, because daptomycin exhibits concentration-dependent killing, we favor higher dosing of 8 to 10 mg/kg IV once daily.
References:
  1. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.
  2. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Ther Chemother 2006; 50:3245.
  3. Lui C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.
  4. Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.
Graphic 114038 Version 5.0